Product Images Metformin Hydrochloride

The table shows the mean percent changes from the baseline in major lipid variables at the final visit of a 24-week study of Metformin Hydrochloride Tablets in three different dosage levels. The variables include total cholesterol, total triglycerides, LDL-cholesterol, and HDL-cholesterol. The table shows the baseline levels for each variable, the number of patients studied, and the mean percent change at the final visit for each dosage level. The data suggests that the dosage levels have varying effects on the lipid variables over the course of the study.*

The text describes a table (Table 7) that summarizes the mean changes from baseline in HbAs, fasting plasma glucose, and body weight at week 12 and at the final visit of a 24-week study. The table compares the changes observed in patients taking different doses of metformin hydrochloride extended-release tablets (500 mg twice daily, 1000 mg once daily, and 1500 mg once daily). The changes in HbA, fasting plasma glucose, and body weight are shown for each dose, along with their corresponding 95% confidence intervals. The text also mentions that all patients were on metformin hydrochloride tablets 500 mg twice daily at baseline.*

This is a summary of the mean percentage changes from baseline of major serum lipid variables at final visit for 29-week studies comparing the effects of Metformin Hydrochloride tablets versus Placebo and Combined Metformin Hydrochloride Tablets/Glyburide versus Monotherapy. The table provides results of the study in a tabular format with the following variables Total Cholesterol, Total Triglycerides, LDL-Cholesterol, and HDL-Cholesterol, as well as the baseline and mean percentage changes at final visit for each treatment arm.*

NuCare Pharmaceuticals, Inc. sells Metformin HCI 1000mg tablets in bottles of 90 with Lot# 000000 and NDC: 68071-4683-09. Each tablet contains Metformin Hydrochloride, and the bottle has MFR NDC: 23155-104-10 and GTIN 0036807146837. The tablets are oval-shaped, white/off-white, and scored with "HM04" on one side. The expiration date is 00-00, and the warning label asks for the product to be kept out of the reach of children and to be stored at a controlled temperature ranging from 59-86°F. If experiencing side effects, please call a doctor for medical advice or report them to FDA at 1.800.FDA-1088.*

This is a description of a study conducted on pediatric patients with a mean age of 13.8 years and a range of 10 to 16 years. All the patients were on diet therapy at baseline, and the study results were not statistically significant.*

This is a tabular summary presenting a comparison between metformin Hydrochloride tablets and placebo in a clinical study that lasted for 29-week. The table shows the mean changes from baseline in fasting plasma glucose, Hemoglobin A, and body weight at the final visit. The study involved 145 patients who took the tablets and 141 patients who took the placebo. Patients were all on diet therapy at baseline. The table shows that metformin Hydrochloride tablets were effective in reducing fasting plasma glucose and Hemoglobin A, but had no significant effect on body weight. The placebo did not have a significant effect on any of the measures.*

This is a summary of the mean changes in plasma glucose and body weight at the final visit between Metformin Hydrochloride Tablets and Placebo in pediatrics. The table shows the baseline and the change at final visit for both FPG and Body Weight. There is a p-value of <0.001 for the change in FPG between the two groups, indicating a significant difference. The change in body weight does not show a significant difference.*

This is a table presenting the results of a study comparing the effects of a combination of metformin hydrochloride tablets and insulin to a placebo plus insulin, in terms of changes in Hemoglobin A1c levels and daily insulin dose. The table shows that the treatment difference is statistically significant for Hemoglobin A1c, but not for daily insulin dose. However, there is a significant change in insulin dose for the insulin-only placebo group.*